活體造影內生性葡萄糖醛酸活性以進行個人化前驅藥物之標靶治療(II)

CNU IR > Pharmacy and Science > Dept. of Pharmacy > MOST Project > Item 310902800/28251

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/28251

Title:	活體造影內生性葡萄糖醛酸活性以進行個人化前驅藥物之標靶治療(II) In vivo imaging of endogenous ？-glucuronidase activity for personalized glucuronide prodrug targeted therapy
Authors:	呂玉玲鄭添祿
Contributors:	嘉南藥理大學藥學系
Date:	2013
Issue Date:	2014-11-05 15:30:14 (UTC+8)
Abstract:	直接測試不同腫瘤細胞內bG-activities, 不同腫瘤細胞間內生性bG-的活性並不相同, 異體移植不同細胞的腫瘤間內生性bG-的活性也不相同, 切片測試和活體照影的結果並不致.利用葡萄醣醛酸造影劑活體評估葡萄醣酸前驅藥物(9-ACG)和CPT-11之標靶治療的療效, 以NIR-TrapG評估bG活性, 與9ACGM的治療效果呈正相關, 另外, 造影劑有bG-活性表現的腫瘤colon 205, 當以CPT-11治療時, 對腫瘤生長的抑制作用比沒有bG-活性表現的腫瘤HCT116明顯有效. In vivo imaging to detect the endogenous b-glucuronidase activity, these have difference amounts of b-glucuronidase activity. Evaluate the therapeutic effect of glucuronide prodrug (9-ACG) in colon tumor, its effect equal with b-glucuronidase activity. Evaluate the therapeutic effect of glucuronide prodrug (CPT-11) in colon tumor with different b-glucuronidase activity, it is efficiency against tumor with highly b-glucuronidase activity than less level.
Relation:	計畫編號：NSC101-2320-B041-001-MY2 計畫年度：102；起迄日期：2013-08-01~2014-07-31
Appears in Collections:	[Dept. of Pharmacy] MOST Project

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1478	View/Open

Loading...